Monoterapie antyandrogenowe
: 23 lut 2018, 10:02
Comparison of bicalutamide with other antiandrogens
Contents
1 Overview
2 First-generation NSAAs
2.1 Effectiveness
2.2 Tolerability and safety
3 Second-generation NSAAs
3.1 Effectiveness
3.2 Tolerability and safety
4 Steroidal antiandrogens
4.1 Effectiveness
4.2 Tolerability and safety
5 Castration and GnRH analogues
5.1 Effectiveness
5.2 Tolerability and safety
6 References
Overview
Bicalutamide and the other nonsteroidal antiandrogens (NSAAs), since their introduction, have largely replaced cyproterone acetate (CPA), an older drug and steroidal antiandrogen (SAA), in the treatment of prostate cancer.[1][2][3][4] Bicalutamide was the third NSAA to be marketed, with flutamide and nilutamide preceding, and followed by enzalutamide.[5][6] Relative to the earlier antiandrogens, bicalutamide has substantially reduced toxicity, and in contrast to them, is said to have an excellent and favorable safety profile.[4][7][8][9] For these reasons, as well as superior potency, tolerability, and pharmacokinetics, bicalutamide is preferred and has largely replaced flutamide and nilutamide in clinical practice.[10][11][12] In accordance, bicalutamide is the most widely used antiandrogen in the treatment of prostate cancer.[13][14][15] Between January 2007 and December 2009, it accounted in the U.S. for about 87.2% of NSAA prescriptions.[16] Prior to the 2012 approval of enzalutamide, a newer and improved NSAA with greater potency and efficacy,[7] bicalutamide was regarded as the standard-of-care antiandrogen in the treatment of the prostate cancer.[6][7][17]
https://en.wikipedia.org/wiki/Compariso ... iandrogens